Allergic contact dermatitis to topical preparations of bufexamac.

Abstract

In Australia bufexamac is mainly used for pharmacist-initiated local treatment of various dermatoses. The European Medicines Agency's Committee for Medicinal Products for Human Use recently recommended that marketing authorisation for bufexamac-containing preparations be revoked throughout the European Union because of the risk of severe allergic contact dermatitis. We retrospectively reviewed the patch test database at the Skin and Cancer Foundation Inc. and identified 19 cases of positive reactions to bufexamac (5% petrolatum) from 451 people patch tested. The bufexamac reaction was deemed relevant to the presenting dermatitis in 13 of 19 (68%) patients. Bufexamac allergic contact dermatitis is under-reported in the English literature. We wish to emphasise the severity and the unusually polymorphic eruptions observed in some of the cases. Clinicians should consider the possibility of allergic contact dermatitis to bufexamac-containing preparations in all patients where there is a history of exposure, even if used for only a short time.

• Authors: Yan Pan, Rosemary Nixon
• Journal: The Australasian journal of dermatology (Australas J Dermatol) Vol. 53 Issue 3 Pg. 207-10 (Aug 2012) ISSN: 1440-0960 [Electronic] Australia
• PMID: 22881467 (Publication Type: Journal Article)
• Copyright: © 2012 The Authors. Australasian Journal of Dermatology © 2012 The Australasian College of Dermatologists.

Chemical References

• Anti-Inflammatory Agents, Non-Steroidal
• Bufexamac

Topics

• Administration, Cutaneous
• Adolescent
• Adult
• Anti-Inflammatory Agents, Non-Steroidal (administration & dosage, adverse effects)
• Bufexamac (administration & dosage, adverse effects)
• Dermatitis, Allergic Contact (etiology)
• Drug Eruptions (etiology)
• Female
• Humans
• Male
• Middle Aged
• Patch Tests
• Young Adult